Alec Morton


United Kingdom
Professor, University of Strathclyde, Glasgow


Alec Morton has degrees from the University of Manchester and the University of Strathclyde. He has worked for Singapore Airlines, the National University of Singapore, and the London School of Economics, has held visiting positions at Carnegie Mellon University in Pittsburgh, Aalto University in Helsinki, and the University of Science and Technology of China (USTC) in Hefei, and has been on secondment at the National Audit Office. His main interests are in decision analysis and health economics, and he is one of the developers of the STAR toolkit sponsored by the Health Foundation.  He is a member of the International Decision Support Initiative and the Health Service Research Center of USTC.

Alec has been active in the INFORMS Decision Analysis Society and the OR Society. He is on the Editorial Board of Decision Analysis and is an Associate Editor for the EURO Journal on Decision Processes, the Transactions of the Institute of Industrial Engineers, and OR Spectrum. Past consulting clients include the National Audit Office, the Department of Health, the Environment Agency, the Nuclear Decommissioning Authority and the Global Fund to Fight AIDS, Tuberculosis & Malaria. His papers have won awards from the International Society for Pharmacoeconomics and Outcomes Research and the Society for Risk Analysis.  His book Portfolio Decision Analysis with Jeff Keisler and Ahti Salo won the INFORMS Decision Analysis Society publication award in 2013 and his paper "CUT: A Multicriteria Approach for Concavifiable Preferences" (with Nikos Argyris and Jose Figueira) was a finalist for the same prize in 2016 .

Learn more about Prof. Morton!

CV_Alec Morton

6 Answers
6 related questions found.

Sample for utility

In terms of number of respondents required for utility data, is there any standardized formula to calculate? And whether it is justifiable to calculate using proportion estimation? In case of the limited sample (e.g. rare disease, low survival rate) and do not meet the expected sample (as calculat...

Asked: 12 Apr 2018  |   1085  |   1 answer

Expected Value of Perfect Information

How useful really is Expected Value of Perfect Information as an additional analysis to support decision-making for the healthcare system? Are there settings/countries now who are conducting this as part of their standard analysis to complement the results of cost effectiveness analysis?

Asked: 30 May 2018  |   1190  |   2 answers

CEA on Road Safety Policies

"Dear professor, Currently, we have so many road safety policies to reduce the number of casualties and deaths. The WHO guideline recommends the use of CEA for policies, measuring the outcomes in terms of death reductions or casualty reductions. The thing is we don't know which specific policy is ac...

Asked: 31 May 2018  |   1172  |   2 answers

Plotting ICER result on cost-effectiveness plane and putting PSA in CEAC

Dear Expert, I have values for both the incremental cost and incremental DALY/QALY. How do I put them on cost-effectiveness plane or how do I plot them in graph, so that I get nice graph showing ICER result on cost-effectiveness plane? number 2: I have all the values from PSA. How do I put them in ...

Asked: 05 Jun 2019  |   1504  |   2 answers

Choice of journal for publication

Which journal should I go for a publication of research on Economic evaluation of vaccine?

Asked: 24 Jun 2019  |   1135  |   3 answers

How to transfer distribution of probability parameter from 5 years into 1 year

Dear Dr and Prof, I'm trying to find probability parameters for my model of chronic hepatitis B. However, most study I found come from observational studies, with different duration of follow-up . In my model, I need the probability and the parameters for beta distribution (alpha, beta). And I don'...

Asked: 29 Feb 2020  |   907  |   3 answers